EUCTR2017-004792-30-GR进行中（未招募）1 期
Phase Ib-II study of Ramucirumab combined with standard Nab-paclitaxel and Gemcitabine as first-line treatment in patients with advanced pancreatic adenocarcinoma - RACING
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Signed and dated written informed consent and willing and able to comply with protocol requirements.
- •2. Histologically or cytologically proven pancreatic adenocarcinoma.
- •3. Metastatic or locally advanced unresectable disease confirmed clinically/radiologically by CT-scan or MRI (Magnetic Resonance Imaging)
- •4. No prior therapy for metastatic disease. Adjuvant Gemcitabine is permitted if 6 or more months have elapsed from last cycle to date of relapse.
- •5. At least one measurable or evaluable lesion as assessed by CT-scan or MRI according to RECIST v1.1
- •6. Age 18 years,
- •7. ECOG Performance status (PS) 0-1
- •8. The patient has adequate hematologic function, as evidenced by an absolute neutrophil count (ANC) 1500/µL, hemoglobin 9 g/dL (5.58 mmol/L), and platelets 100,000/µL.
- •9. The patient must have adequate coagulation function as defined by International Normalized Ratio (INR) 1.5, and a partial thromboplastin time (PTT) 5 seconds above the ULN (unless receiving anticoagulation therapy). Patients receiving warfarin must be switched to low molecular weight heparin and have achieved stable coagulation profile prior to first dose of protocol therapy
- •10. The patient has adequate renal function as defined by a serum creatinine 1.5 times the ULN, or creatinine clearance (measured via 24-hour urine collection) 40 mL/minute (that is, if serum creatinine is >1.5 times the ULN, a 24-hour urine collection to calculate creatinine clearance must be performed).
- •11. The patient has adequate hepatic function as defined by a total bilirubin 1.5 mg/dL (25.65 µmol/L), and aspartate transaminase (AST) and alanine transaminase (ALT) 2.5 times the upper limit of normal (ULN; or 5.0 times the ULN in the setting of liver metastases)
- •12. The patient’s urinary protein is 1+ on dipstick or routine urinalysis (UA; if urine dipstick or routine analysis is 2+, a 24-hour urine collection for protein must demonstrate <1000 mg of protein in 24 hours to allow participation in this protocol).
- •13. Regular follow-up feasible
- •14. Baseline evaluations performed before treatment initiation: clinical and blood evaluations no more than 2 weeks (14 days) prior to treatment initiation, tumor assessment (chest X ray, CT-scan or MRI, evaluation of non-measurable lesions) no more than 4 weeks (28 days) prior to treatment initiation,
- •15. First course of treatment planned less than 1 week (7 days) after registration,
- •16. Because the teratogenicity of ramucirumab is not known, the patient, if sexually active, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods).
- •17. Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dose of protocol therapy.
- •18. Female patients must commit to using reliable and appropriate methods of contraception during the trial until at least three months after the end of study treatment (when applicable). Male patients with a partner of childbearing potential must agree to use contraception in addition to having their partner use another reliable contraceptive method during the trial until at least 6 months after the end of study treatment.
- •19. Patients must have a low or intermediate risk of arterial or venous thrombotic events (Khorana risk score 0-2). Patients at a high VTE risk (Khorana RS3) are eligible if they receive LMWH prophylaxis (Appendix D).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64
排除标准
- •1.The patient has pancreatic cancer with histology other than adenocarcinoma
- •2.Prior therapy for metastatic disease. Adjuvant Gemcitabine is permitted if 6 or more months have elapsed from last cycle to date of relapse.
- •3.Exclusive presence of bone metastasis only
- •4.Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy)
- •5.Treatment with any other investigational medicinal product within 28 days prior to study entry
- •6.Other serious and uncontrolled non-malignant chronic disease
- •7.The patient has:
- •- cirrhosis at a level of Child-Pugh B (or worse) or- cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis.
- •- Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis.
- •8.The patient has documented brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression. Screening of asymptomatic patients is not required.
- •9.Treatment with CYP3A4 or CYP2C8 inducers or inhibitors, unless discontinued > 7 days prior to prior to first dose of protocol therapy
- •10. The patient is receiving chronic antiplatelet therapy, including aspirin, nonsteroidal antiinflammatory drugs (NSAIDs, including ibuprofen, naproxen, and others), dipyridamole or clopidogrel, or similar agents. Once-daily aspirin use (maximum dose 325mg/day) is permitted.
- •11.The patient has experienced grade 3-4 gastrointestinal bleeding (unless due to resected tumor), treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, or diverticulitis within 3 months prior to first dose of protocol therapy.
- •12.Other concomitant or previous malignancy, except: i/ adequately treated in-situ carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin, iii/ cancer in complete remission for >5 years
- •13.Any other serious and uncontrolled non-malignant disease within the last 28 days
- •14.Pregnant or breastfeeding women
- •15.Patients with known allergy to any excipients to study drugs
- •16.The patient has symptomatic congestive heart failure (CHF; New York Heart Association II-IV) or symptomatic or poorly controlled cardiac arrhythmia
- •17.Bowel obstruction
- •18.The patient has a prior history of GI perforation/fistula (within 6 months of first dose of protocol therapy) or risk factors for perforation.
- •19.The patient has a serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to first dose of protocol therapy.
- •20.The patient has undergone major surgery within 28 days prior to first dose of protocol therapy, or minor surgery/subcutaneous venous access device placement within 7 days prior to first dose of protocol therapy.
- •21.The patient has elective or planned major surgery to be performed during the course of the clinical trial.
- •22.History of severe tumor bleeding or bleeding disorders. The patient has experienced any Grade 3-4 GI bleeding within 3 months prior to first dose of protocol therapy.
- •23.Inadequate coagulation function as defined by International Normalized Ratio (INR) > 1.5, and a partial thromboplastin time (PTT) >5 seconds above the ULN (unless receiving anticoagulation therapy- only low molecular weight heparin injections permitted).
- •24.Palliative radiation therapy within 4 weeks prior to registration
- •25.The patient has experienced any arterial thromboembolic events, including but not limited to myocardial infarction, transient isch
研究者
相似试验
进行中（未招募）
2 期
Phase II study of ramucirumab in combination with erlotinib for untreated EGFR mutation-positive non-squamous non-small cell lung cancer patients with pleural effusion: RELAY-EffusioEGFR mutation positive advanced non-small cell lung cancerJPRN-jRCTs051210138Kaneda Hiroyasu40
未知
1 期
Phase 1b Study of Ramucirumab in Combination With Fluoropyrimidines and Platinum-Based Agents in Japanese Patients With Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaStomach NeoplasmsJPRN-jRCT2080222764Eli Lilly Japan K.K.
招募中
2 期
Phase II study of ramucirumab for the patients with advanced hepatocellular carcinoma previously treated with lenvatinibHepatocellular carcinomaJPRN-jRCT1041190083Yamashita Tatsuya33
未知
2 期
A Phase 2 Study of Ramucirumab in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First Line Platinum- or Fluoropyrimidine-Containing Combination Therapy in Japanese PatientsGastric CancerJPRN-jRCT2080222292Eli Lilly Japan K.K.
已完成
不适用
A multicenter phase II study of S-1+ramucirumab as first line treatment in elderly patients with advanced/recurrent gastric cancer(KSCC1701)gastric cancerJPRN-UMIN000028309Kyushu Study group of Clinical Cancer48